The main aims of VIVEbiotech´s participation in this conference are:

  • Meeting with biotech/pharma companies developing a gene therapy pipeline and encompassing the use of lentiviral vectors, companies that require bioprocess development or manufacturing services.
  • Meeting with companies developing a pipeline of early-stage gene therapy compounds for which LENTISOMA presents very interesting advantages comparing to current LV vectors.
  • Meeting with KOLs, associations and consultants specialized in the gene therapy field to enhance and continue building VIVEbiotech´s network.